Sculpher M, Poole L, Cleland J, Drummond M, Armstrong P, Horowitz J, et al. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. Eur J Heart Fail. 2000;2:447-54 pubmed
..The ATLAS Study showed that the treatment of heart failure with high-doses of lisinopril has a high probability of being more cost-effective than low-dose therapy. ..
Sculpher M, Drummond M. Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions?. Pharmacoeconomics. 2006;24:1087-99 pubmed
..Expected value of information analyses are also emerging as a tool that could be considered by decision makers to guide their policy on the acceptance or non-acceptance of data from other jurisdictions. ..
Sculpher M. Reflecting heterogeneity in patient benefits: the role of subgroup analysis with comparative effectiveness. Value Health. 2010;13 Suppl 1:S18-21 pubmed publisher